Every year, around 500,000 people suffer from spinal cord acute injuries due to a variety of reasons, most commonly as a result of car accidents, work and sport accidents and more. The inability of the neuro cells in the Central Nerve System to regenerate leaves the majority of patients without a cure and with severe limitations. NurExone Biologic aims to change this status-quo. The company is developing a treatment based on revolutionary biological extracellular vesicles (EV) technology to treat traumatic damage in the Central Nerve System (CNS). The ground-breaking Exosome technology at NurExone has the potential to provide a much sought-after treatment for Spinal Cord Injuries (SCI). read more